Cracking The Code: Understanding Analyst Reviews For Travere Therapeutics – Travere Therapeutics (NASDAQ:TVTX)

During the last three months, 7 analysts shared their evaluations of Travere Therapeutics TVTX, revealing diverse outlooks from bullish to bearish.

In the table below, you’ll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 3 0 4 0 0
Last 30D 0 0 1 0 0
1M Ago 0 0 0 0 0
2M Ago 3 0 2 0 0
3M Ago 0 0 1 0 0

Analysts have set 12-month price targets for Travere Therapeutics, revealing an average target of $12.29, a high estimate of $20.00, and a low estimate of $7.00. This current average has decreased by 0.89% from the previous average price target of $12.40.

Analyzing Analyst Ratings: A Detailed Breakdown

The standing of Travere Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Nicole Gabreski Piper Sandler Raises Neutral $11.00 $10.00
Alex Thompson Stifel Raises Hold $10.00 $8.00
Ed Arce HC Wainwright & Co. Raises Buy $20.00 $18.00
Carly Kenselaar Citigroup Raises Buy $10.00 $7.00
Ed Arce HC Wainwright & Co. Maintains Buy $18.00
Carly Kenselaar Citigroup Announces Neutral $7.00
Nicole Gabreski Piper Sandler Lowers Neutral $10.00 $19.00

Key Insights:

  • Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they ‘Maintain’, ‘Raise’, or ‘Lower’ their stance, it signifies their response to recent developments related to Travere Therapeutics. This offers insight into analysts’ perspectives on the current state of the company.
  • Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from ‘Outperform’ to ‘Underperform’. These ratings convey expectations for the relative performance of Travere Therapeutics compared to the broader market.
  • Price Targets: Understanding forecasts, analysts offer estimates for Travere Therapeutics’s future value. Examining the current and prior targets provides insight into analysts’ changing expectations.

Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Travere Therapeutics’s market standing. Stay informed and make data-driven decisions with our Ratings Table.

Stay up to date on Travere Therapeutics analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Discovering Travere Therapeutics: A Closer Look

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) – rare kidney disorders that often cause end-stage kidney disease.

Financial Insights: Travere Therapeutics

Market Capitalization Analysis: The company’s market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.

Revenue Growth: Travere Therapeutics displayed positive results in 3 months. As of 30 September, 2023, the company achieved a solid revenue growth rate of approximately 32.13%. This indicates a notable increase in the company’s top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Travere Therapeutics’s financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 406.35%, the company showcases strong profitability and effective cost management.

Return on Equity (ROE): Travere Therapeutics’s financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 76.08%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): Travere Therapeutics’s financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 19.21%, the company showcases efficient use of assets and strong financial health.

Debt Management: Travere Therapeutics’s debt-to-equity ratio stands notably higher than the industry average, reaching 1.45. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.

The Core of Analyst Ratings: What Every Investor Should Know

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish “analyst ratings” for stocks. Analysts typically assess and rate each stock once per quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Source link

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button